This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Statement Highlights: Previous studies have found that 14-81% of patients with heartfailure experience some degree of cognitive impairment affecting language, memory or executive function. Evidence also indicates that people with atrialfibrillation.
This secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With HeartFailure (FINEARTS-HF) randomized clinical trial examines the efficacy and safety of finerenone in patients with heartfailure with mildly reduced or preserved ejection fraction according to the presence and type of atrialfibrillation. (..)
Background Heartfailure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heartfailure with reduced ejection fraction is more common. fold higher risk of heartfailure with preserved ejection fraction (95% CI 1.30 m/s had a 2.10-fold
Three common cardiovascular diseases in adults—heartfailure, atrialfibrillation and coronary heart disease—are linked to cognitive impairment and increased risk of dementia, according to "Cardiac Contributions to Brain Health," a new scientific statement from the American Heart Association published today in the journal, Stroke.
It highlights the confluence of two major cardiovascular epidemics, atrialfibrillation and heartfailure, with preserved ejection fraction. In these conditions, advances in electrophysiology and heartfailure physiology are intertwined and are integrated in this review.
Atrialfibrillation is the most prevalent arrhythmia with a lifetime risk of nearly 30%. It can be associated with reduced quality of life and complications such as heartfailure and stroke. Pulmonary vein isolation (PVI) is the most effective treatment for rhythm control.
atrialfibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime. In the U.S.,
Two studies led by researchers at the Broad Institute of MIT and Harvard and Mass General Brigham have greatly expanded the number of known genetic variants that boost the risk for atrialfibrillation (AF), a common heart condition marked by an irregular heartbeat that can lead to stroke and heartfailure.
Atrialfibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. This condition can lead to various complications, including stroke and heartfailure, making it essential to understand its causes, symptoms, and AFib treatment options. What is AtrialFibrillation?
Radiofrequency ablation (RFA) is an important therapeutic modality for atrialfibrillation (AF), widely utilized in clinical practice due to its safety and significant efficacy. Head CT scans showed hypoattenuating areas indicative of cerebral infarction, chest CT suggested possible air accumulation in the left atrial region.
Background Atrialfibrillation (AF) is a major and increasing burden on health services. This study aimed to evaluate the cost-effectiveness of digoxin versus beta-blockers for heart rate control in patients with permanent AF and symptoms of heartfailure.
In adults with congenital heart disease (ACHD patients), atrial arrhythmias (AA) and heartfailure (HF) are common. 1 Factors related to congenital heart disease, such as underlying anatomy, surgical repair technique and scars, can all be considered as AA substrates.
This systematic review and meta-analysis investigates the efficacy of catheter ablation compared with rate or rhythm control among patients with atrialfibrillation and heartfailure.
Millions of adults have atrialfibrillation—an irregular beating of the upper chambers of the heart that yields increased risk of heartfailure, stroke and death.
Heartfailure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. Common predictors include older age, prior hypertension, diabetes and atrialfibrillation. HFrEF is more commonly.
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heartfailure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25
In their study, published in Nature Cardiovascular Research they found that Black individuals carrying these genetic variants were at a high risk of developing atrialfibrillation and heartfailure.
Background We evaluated the potential of circulating bone morphogenetic protein 10 (BMP10) as a biomarker for atrial stress and remodelling in patients with heartfailure (HF), in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP). We also assessed the predictive value of BMP10 for adverse clinical outcomes.
Background Atrialfibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both conditions. Whether the risks of outcomes differ according to temporal order of AF and AMI is unclear.
(MedPage Today) -- The efficacy of catheter ablation for heartfailure (HF) patients with atrialfibrillation (Afib or AF) hinged on the phenotype of disease, researchers reported based on a meta-analysis. Compared with conventional rate or rhythm.
An international consensus statement on how to treat atrialfibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany.
A secondary analysis of FINEARTS-HF found consistent efficacy of finerenone on heartfailure events and cardiovascular death, irrespective of AF status.
A new American Heart Association scientific statement suggests addressing cardiovascular health earlier in life may reduce the risk of stroke and help preserve thinking and memory later in life.
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heartfailure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with HeartFailure with Preserved Ejection Fraction (HFpEF).
Atrialfibrillation, or AFib, is a fast and irregular heart rhythm that, left untreated, can lead to blood clots, stroke and heartfailure. It's the most common type of arrhythmia, a potentially serious condition in which the heart beats too quickly, too slowly or in an irregular pattern.
Atrialfibrillation (AF) significantly increases the risk of stroke and heartfailure, but is frequently asymptomatic and intermittent; therefore, its timely diagnosis poses challenges.
About AtrialFibrillation and Pulsed Field Ablation AF is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide3. 4-7 Current ablation technologies rely on thermal effects to target cardiac tissue and risk damage to additional collateral structures in the heart.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. Circulation.
Atrialfibrillation is the most common cardiac arrhythmia worldwide with around 59 million people concerned in 2019. This irregular heartbeat is associated with increased risks of heartfailure, dementia and stroke. It gives early warnings on average 30 minutes before onset, with an accuracy of around 80%.
A new artificial intelligence (AI) model designed by Scripps Research scientists could help clinicians better screen patients for atrialfibrillation (or AFib)—an irregular, fast heartbeat that is associated with stroke and heartfailure.
The collaboration, according to a written statement issued by the company, aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrialfibrillation procedures. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.
Introduction Catheter ablation is an effective and safe strategy for treating atrialfibrillation patients. Method Patient baseline characteristics and electrophysiological parameters were examined to identify the predictors of atrialfibrillation recurrence following catheter ablation. years following catheter ablation.
Heartfailure with preserved ejection fraction (HFpEF) and atrialfibrillation (AF) have emerged as major age-related epidemics within cardiology. Indeed, these two conditions are commonly found in the same individual, so much so that AF has been used in proposed diagnostic criteria for HFpEF.
All statistical analyses were rigorously executed in R software.ResultsOur findings identified causal relationships between 15 metabolites and cardiovascular disease.
Breakdown of the study population by worsening heartfailure (WHF) event proportions (oral diuretic intensification or heartfailure [HF] hospitalization) and KaplanMeier curve of all-cause mortality after WHF event shown, relative to a patient group that did not have any WHF events. per 100 person-years; 95% CI 17.750.3)
Early detection of atrialfibrillation can reduce the risk of stroke and heartfailure, but screening people for the condition has been historically challenging.
Introduction A high recurrence rate of atrialfibrillation was monitored after catheter ablation for persistent atrialfibrillation. The results will evaluate sacubitril/valsartan as a novel treatment for improving prognosis and a complement to conventional drug therapy.
Monitoring of heart rate and physical activity using consumer wearable devices was found to have clinical value for comparing the response to two treatments for atrialfibrillation and heartfailure.
Background Heartfailure (HF) is not included in atrialfibrillation (AF) bleeding risk prediction scores, reflecting uncertainty regarding its importance as a risk factor for major haemorrhage.
What is the prevalence of subclinical atrialfibrillation (AF) in patients with heartfailure and preserved ejection fraction (HFpEF), and how does it impact outcomes?
Current guideline indications for intervention in asymptomatic patient are centred on left ventricular dimensions and ejection fraction and may include consideration in atrialfibrillation, pulmonary hypertension and those with left atrial dilatation.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content